Chemical Structure (Alecensa 01)
Alecensa Capsule
Product Images NDC 50242-130
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Alecensa (NDC 50242-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Alecensa 02)
This appears to be a part of a graph or table that displays the number of individuals at risk for either taking Crizotinib or Alectinib at specific time intervals of 13, 16, 9, 12, 15, 18, 21, 24, 27, and 30 months. The table also lists the medication names and the dosages (@60 for Alectinib) of the drugs but does not provide adequate context or information to determine the medical condition or purpose of taking the medication.*
Alecensa 03
Alecensa® is a medication available in capsule form with NDC code 50242-130-01. Each capsule contains 150 mg of alectinib, which is equivalent to 161.33 mg of alectinib HCl. The package comes with 240 capsules manufactured by Genentech under the name Ronly.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
